A new oral antiviral drug candidate has been developed for the treatment of diseases caused by orthoparamyxoviruses, such as ...

As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed. In this podcast, Anil Diwan, President and Executive Chairman of ...

A new oral antiviral drug candidate has been developed for the treatment of diseases caused by orthoparamyxoviruses, such as ...

Ensitrelvir marks a breakthrough in anti-COVID treatment, paving the way for future defenses against betacoronaviruses.

SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

Researchers at the Nanoscience Initiative at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have made a breakthrough in the fight against viral diseases. Their study, ...

Traws Pharma, Inc. TRAW shares are up during Friday’s session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections. Traws ...

Headshot of Sumit Chanda standing outside Scripps Research Institute. Sumit Chanda has dedicated his career to antiviral drug research. Credit: Courtesy of the Chanda Lab The US National Institutes of ...

Global health authorities are racing to identify medical options to help contain an Ebola outbreak in eastern Democratic ...

Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza (baloxavir marboxil) ...

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the ...